SCHEMBL24124181

SCHEMBL24124181

CN(Cc1cccc(NC(=O)c2ccc3c(c2)CCCS3)c1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGES O14684 1/20 0.44
▸ NPC1 O15118 4/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ MCHR1 Q99705 1/20 0.43
▸ MAPT P10636 4/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ KCNK3 O14649 1/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ NCOR2 Q9Y618 1/20 0.41
▸ LOXL2 Q9Y4K0 1/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ TRPV1 Q8NER1 2/20 0.40
▸ ACKR3 P25106 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124184 0.90 HDAC1 (0.47) NPC1RAB9AMCHR1MAPTALDH1A1
SCHEMBL24124166 0.83 HDAC8 (0.48) NPC1RAB9AMAPTHDAC3HDAC1
SCHEMBL24124175 0.79 USP7 (0.52) RAB9AMAPTALDH1A1TRPV1ACKR3
SCHEMBL24124243 0.76 NPC1 (0.50) NPC1RAB9AMAPTALDH1A1KMT2A
SCHEMBL25921521 0.76 MAPT (0.61) NPC1RAB9AMAPTALDH1A1LMNA
SCHEMBL25921185 0.76 MAPT (0.46) NPC1RAB9AMAPTALDH1A1HDAC3
SCHEMBL24124737 0.76 MAPT (0.40) NPC1RAB9AMAPTALDH1A1LMNA
SCHEMBL24125238 0.75 NPC1 (0.43) NPC1RAB9AMAPTLMNAHDAC1
SCHEMBL25920824 0.75 MAPT (0.52) NPC1RAB9AMAPTALDH1A1LMNA
SCHEMBL24124178 0.74 HDAC3 (0.54) PTGESKCNK3HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 PTGES 2204/4885NPC1 2197/4885RAB9A 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback